Here, we have examined their in vitro and in vivo actions on multiple cancer types, selectivity for killing transformed cells, effects on cancer cell migration, capacity to act in combination with other cancer therapeutics, interference with transcription of known direct CEBPB, CEBPD and ATF5 targets and distal mechanisms of action by which they kill malignant cells. This evidence concerns the gene CEBPB and cancer.